The effect of intracellular protein delivery on the anti-tumor activity of recombinant human endostatin

Junghee Lim, Tam Duong, Guewha Lee, Baik Lin Seong, Wael El-Rifai, H. Earl Ruley, Daewoong Jo

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Endostatin (ES), a 20kDa protein derived from the carboxy-terminus of collagen XVIII is a potent angiogenesis inhibitor, but clinical development has been hindered by poor clinical efficacy and insufficient functional information from which to design agents with improved activity. The present study investigated protein uptake by cells as a determinant of ES activity. We developed a cell-permeable ES protein (HM73ES) with enhanced capacity to enter cells by adding a macromolecule transduction domain (MTD). HM73ES inhibited angiogenesis-associated phenotypes in cultured endothelial cells [as assessed by tube formation, wound-healing, cell proliferation and survival assays]. These effects were accompanied by reductions in MAPK signaling (ERK phosphorylation), and in β-Catenin, c-Myc, STAT3, and VEGF protein expression. The cell-permeable ES displayed greater tissue penetration in mice and suppressed the growth of human tumor xenografts to a significantly greater extent than ES protein without the MTD sequence. Our results suggest that anti-angiogenic activities of native ES are limited at the level of protein uptake and/or subcellular localization, and that much of the activity of ES against tumors depends on one or more intracellular functions. This study will inform future efforts to understand ES function(s) and suggest strategies for improving ES-based cancer therapeutics.

Original languageEnglish
Pages (from-to)6261-6271
Number of pages11
JournalBiomaterials
Volume34
Issue number26
DOIs
Publication statusPublished - 2013 Aug 1

Fingerprint

Endostatins
Human Activities
Tumors
Proteins
Neoplasms
Macromolecules
Phosphorylation
Endothelial cells
Cell proliferation
Collagen Type XVIII
Collagen
Catenins
STAT3 Transcription Factor
Assays
Angiogenesis Inhibitors
Tissue
Heterografts
Wound Healing
Vascular Endothelial Growth Factor A
Cultured Cells

All Science Journal Classification (ASJC) codes

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

Cite this

Lim, Junghee ; Duong, Tam ; Lee, Guewha ; Seong, Baik Lin ; El-Rifai, Wael ; Ruley, H. Earl ; Jo, Daewoong. / The effect of intracellular protein delivery on the anti-tumor activity of recombinant human endostatin. In: Biomaterials. 2013 ; Vol. 34, No. 26. pp. 6261-6271.
@article{6bc99473c2d64f29902cb39212d8a4e4,
title = "The effect of intracellular protein delivery on the anti-tumor activity of recombinant human endostatin",
abstract = "Endostatin (ES), a 20kDa protein derived from the carboxy-terminus of collagen XVIII is a potent angiogenesis inhibitor, but clinical development has been hindered by poor clinical efficacy and insufficient functional information from which to design agents with improved activity. The present study investigated protein uptake by cells as a determinant of ES activity. We developed a cell-permeable ES protein (HM73ES) with enhanced capacity to enter cells by adding a macromolecule transduction domain (MTD). HM73ES inhibited angiogenesis-associated phenotypes in cultured endothelial cells [as assessed by tube formation, wound-healing, cell proliferation and survival assays]. These effects were accompanied by reductions in MAPK signaling (ERK phosphorylation), and in β-Catenin, c-Myc, STAT3, and VEGF protein expression. The cell-permeable ES displayed greater tissue penetration in mice and suppressed the growth of human tumor xenografts to a significantly greater extent than ES protein without the MTD sequence. Our results suggest that anti-angiogenic activities of native ES are limited at the level of protein uptake and/or subcellular localization, and that much of the activity of ES against tumors depends on one or more intracellular functions. This study will inform future efforts to understand ES function(s) and suggest strategies for improving ES-based cancer therapeutics.",
author = "Junghee Lim and Tam Duong and Guewha Lee and Seong, {Baik Lin} and Wael El-Rifai and Ruley, {H. Earl} and Daewoong Jo",
year = "2013",
month = "8",
day = "1",
doi = "10.1016/j.biomaterials.2013.05.011",
language = "English",
volume = "34",
pages = "6261--6271",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "26",

}

The effect of intracellular protein delivery on the anti-tumor activity of recombinant human endostatin. / Lim, Junghee; Duong, Tam; Lee, Guewha; Seong, Baik Lin; El-Rifai, Wael; Ruley, H. Earl; Jo, Daewoong.

In: Biomaterials, Vol. 34, No. 26, 01.08.2013, p. 6261-6271.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effect of intracellular protein delivery on the anti-tumor activity of recombinant human endostatin

AU - Lim, Junghee

AU - Duong, Tam

AU - Lee, Guewha

AU - Seong, Baik Lin

AU - El-Rifai, Wael

AU - Ruley, H. Earl

AU - Jo, Daewoong

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Endostatin (ES), a 20kDa protein derived from the carboxy-terminus of collagen XVIII is a potent angiogenesis inhibitor, but clinical development has been hindered by poor clinical efficacy and insufficient functional information from which to design agents with improved activity. The present study investigated protein uptake by cells as a determinant of ES activity. We developed a cell-permeable ES protein (HM73ES) with enhanced capacity to enter cells by adding a macromolecule transduction domain (MTD). HM73ES inhibited angiogenesis-associated phenotypes in cultured endothelial cells [as assessed by tube formation, wound-healing, cell proliferation and survival assays]. These effects were accompanied by reductions in MAPK signaling (ERK phosphorylation), and in β-Catenin, c-Myc, STAT3, and VEGF protein expression. The cell-permeable ES displayed greater tissue penetration in mice and suppressed the growth of human tumor xenografts to a significantly greater extent than ES protein without the MTD sequence. Our results suggest that anti-angiogenic activities of native ES are limited at the level of protein uptake and/or subcellular localization, and that much of the activity of ES against tumors depends on one or more intracellular functions. This study will inform future efforts to understand ES function(s) and suggest strategies for improving ES-based cancer therapeutics.

AB - Endostatin (ES), a 20kDa protein derived from the carboxy-terminus of collagen XVIII is a potent angiogenesis inhibitor, but clinical development has been hindered by poor clinical efficacy and insufficient functional information from which to design agents with improved activity. The present study investigated protein uptake by cells as a determinant of ES activity. We developed a cell-permeable ES protein (HM73ES) with enhanced capacity to enter cells by adding a macromolecule transduction domain (MTD). HM73ES inhibited angiogenesis-associated phenotypes in cultured endothelial cells [as assessed by tube formation, wound-healing, cell proliferation and survival assays]. These effects were accompanied by reductions in MAPK signaling (ERK phosphorylation), and in β-Catenin, c-Myc, STAT3, and VEGF protein expression. The cell-permeable ES displayed greater tissue penetration in mice and suppressed the growth of human tumor xenografts to a significantly greater extent than ES protein without the MTD sequence. Our results suggest that anti-angiogenic activities of native ES are limited at the level of protein uptake and/or subcellular localization, and that much of the activity of ES against tumors depends on one or more intracellular functions. This study will inform future efforts to understand ES function(s) and suggest strategies for improving ES-based cancer therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84878623835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878623835&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2013.05.011

DO - 10.1016/j.biomaterials.2013.05.011

M3 - Article

VL - 34

SP - 6261

EP - 6271

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 26

ER -